Kolexia
Chauchet Adrien Hématologie
Chauchet Adrien
Hématologie
Hôpital Jean-Minjoz
Besançon, France
122 Activités
29 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Lymphomes Lymphome B Maladie de Hodgkin Lymphome B diffus à grandes cellules Lymphome T Récidive tumorale locale Tumeurs du système nerveux central Lymphome malin non hodgkinien Échinococcose

Collaborateurs

Voir plus
Morschhauser Franck
Morschhauser Franck
Centre Hospitalier de Lille, Lille, France
Ghesquieres Herve
Ghesquieres Herve
Hôpital Lyon Sud, Pierre-Bénite, France
Houot Roch
Houot Roch
Hôpital Pontchaillou, Rennes, France
Casasnovas Rene-Olivier
Casasnovas Rene-Olivier
Hôpital François Mitterrand, Dijon, France

Industries

Voir plus
Novartis
6 collaboration(s)
Dernière en 2021
Janssen
5 collaboration(s)
Dernière en 2023
Takeda Pharmaceutical
4 collaboration(s)
Dernière en 2023
Kyowa Kirin
3 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
POLARIX: A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination With Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With Diffuse Large B-Cell Lymphoma
Essai Clinique (Roche)   15 mars 2024
MorningLyte: A Phase III Randomized, Open-label, International, Multicenter Study Evaluating the Efficacy and Safety of Mosunetuzumab Plus Lenalidomide in Comparison to Anti-CD20 Monoclonal Antibody Plus Chemotherapy in Subjects With Previously Untreated FLIPI 2-5 Follicular Lymphoma
Essai Clinique (The Lymphoma Academic Research Organisation)   13 mars 2024
LOC-R01: Randomized Phase IB/II Study of Escalating Doses of Lenalidomide and Ibrutinib in Association With R-MPV as a Targeted Induction Treatment for Patients Aged 18 to 60 (up to 65 for Phase II) With a Newly Diagnosed Primary Central Nervous System Lymphoma
Essai Clinique (Institut Curie)   10 janvier 2024
Efficacy of Chimeric Antigen Receptor T-Cell Therapy Is Not Impaired By Previous Bispecific Antibody Treatment in Patients with Large B-Cell Lymphoma
65th ASH Annual Meeting Abstracts   02 novembre 2023
CD19-Targeting CAR T-Cell Therapy in Transformed Waldenström Macroglobulinemia/Lymphoplasmacytic Lymphoma: A Descar-T and US Collaborative Study
65th ASH Annual Meeting Abstracts   02 novembre 2023
Verlen, “Very Elderly Rituximab Associated to Lenalidomide - Tafasitamab Combination in Frontline DLBCL Patients”, a Phase II Open-Label Study Evaluating Efficacy of Lenalinomide and Tafasitamab Combination Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older from the Lysa Group
65th ASH Annual Meeting Abstracts   02 novembre 2023
Challenges for quality and utilization of real-world data for diffuse large B-cell lymphoma in REALYSA, a LYSA cohort.
Blood advances   24 octobre 2023
Salvage therapy with brentuximab-vedotin and bendamustine for patients with R/R PTCL: a retrospective study from the LYSA group.
Blood advances   23 octobre 2023
French Register Of Patients With Hemopathy Eligible For CAR-T Cell Treatment (DESCAR-T)
Essai Clinique (Novartis)   25 septembre 2023
Predictive Factors of Response to Immunotherapy in Lymphomas: A Multicentre Clinical Data Warehouse Study (PRONOSTIM).
Cancers   09 août 2023